Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment through its lead drug candidate ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). In a recent episode of the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed detailed the company’s strategy and the scientific rationale behind ONC010.
Dr. Mohamed emphasized two key selectivity mechanisms that differentiate ONC010. The first is synthetic lethality, which is designed to limit the drug’s lethality to cancer cells that have lost PTEN or SHP-1. The second is nanoparticle delivery, which is intended to concentrate the drug within tumor tissue. These mechanisms aim to enhance the drug’s efficacy while minimizing harm to healthy cells.
Preclinical research conducted at the University of Alberta has shown promising results. According to Dr. Mohamed, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings support the potential of ONC010 as a targeted therapy for cancers with specific genetic vulnerabilities.
Onco-Innovations holds an exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The company is now planning its first-in-human clinical program for ONC010, a critical step toward bringing this innovative treatment to patients.
The significance of this development lies in its potential to address unmet needs in oncology. By targeting PNKP, Onco-Innovations is exploring a new avenue in cancer therapy that could offer benefits to patients who have limited treatment options. The dual selectivity mechanisms may also reduce side effects commonly associated with traditional chemotherapies, improving quality of life during treatment.
For investors and industry observers, the progress of ONC010 underscores Onco-Innovations’ commitment to pioneering cancer research. The company’s focus on a novel target and its use of advanced nanoparticle delivery technology position it at the forefront of DNA damage response therapeutics. As the clinical program advances, further data will be needed to confirm the preclinical findings in human trials.
The podcast interview with Dr. Mohamed provides valuable insights into the company’s scientific approach and strategic direction. To view the full press release, visit https://ibn.fm/XgpMR. For the latest news and updates relating to ONNVF, visit the company’s newsroom at https://ibn.fm/ONNVF. More information about BioMedWire is available at https://www.BioMedWire.com, and full terms of use and disclaimers can be found at https://www.BioMedWire.com/Disclaimer.
